ReShape Lifesciences closes upsized $10.2M public offering of units with warrants

Vyome Holdings, Inc

Offered 1,275,000 units at $8.00/unit; each unit: 1 share (or pre-funded warrant) + 1 warrant for 1.5 shares.
Gross proceeds $10.2M; net proceeds ~$9.1M after underwriting discounts and expenses.
Warrants: exercise price $8.00/share, 5-year term; alternative cashless exercise yields 0.75 shares per warrant.
Overallotment exercised for additional warrants to purchase 286,875 shares of common stock.
Proceeds to fund growth strategies, working capital, and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vyome Holdings, Inc entered into Underwriting Agreement with Maxim Group LLC valued at $8.00 per Unit (effective 2023-02-06).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Value: $8.00 per Unit
Effective: 2023-02-06

Exact text from the filing

On February 6, 2023, ReShape Lifesciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC

View on SEC.gov

Browse all material agreements →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-018505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.